
Frank Siebenhaar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9351371/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 734-766.	5.7	392
2	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. Journal of Allergy and Clinical Immunology, 2016, 137, 35-45.	2.9	289
3	High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study. Journal of Allergy and Clinical Immunology, 2009, 123, 672-679.	2.9	187
4	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1125-1133.e1.	3.8	150
5	Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1267-1274.	5.7	139
6	Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. International Archives of Allergy and Immunology, 2011, 154, 177-180.	2.1	133
7	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere, 2021, 5, e646.	2.7	128
8	Skin mast cells control T cellâ€dependent host defense in Leishmania major infections. FASEB Journal, 2006, 20, 2460-2467.	0.5	123
9	Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clinical and Experimental Dermatology, 2007, 32, 241-245.	1.3	105
10	Mast cell functions in the innate skin immune system. Immunobiology, 2008, 213, 251-260.	1.9	104
11	Mast Cells as Drivers of Disease and Therapeutic Targets. Trends in Immunology, 2018, 39, 151-162.	6.8	103
12	Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 230-238.	5.7	88
13	Control of Pseudomonas aeruginosa Skin Infections in Mice Is Mast Cell-Dependent. American Journal of Pathology, 2007, 170, 1910-1916.	3.8	80
14	Mast cell–driven skin inflammation is impaired in the absence of sensory nerves. Journal of Allergy and Clinical Immunology, 2008, 121, 955-961.	2.9	75
15	Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nature Reviews Immunology, 2022, 22, 294-308.	22.7	72
16	Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. Journal of Allergy and Clinical Immunology, 2007, 120, 213-215.	2.9	57
17	Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. International Journal of Molecular Sciences, 2020, 21, 9030.	4.1	56
18	Mast cells are critical for controlling the bacterial burden and the healing of infected wounds. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20500-20504.	7.1	55

#	Article	IF	CITATIONS
19	Total IgE as a Marker for Chronic Spontaneous Urticaria. Allergy, Asthma and Immunology Research, 2021, 13, 206.	2.9	55
20	Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 816-819.	5.7	53
21	Treatment Strategies in Mastocytosis. Immunology and Allergy Clinics of North America, 2014, 34, 433-447.	1.9	53
22	Mast Cells Limit the Exacerbation of Chronic Allergic Contact Dermatitis in Response to Repeated Allergen Exposure. Journal of Immunology, 2016, 197, 4240-4246.	0.8	50
23	Validation of the Angioedema Control Test (AECT)—A Patient-Reported Outcome Instrument for Assessing Angioedema Control. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2050-2057.e4.	3.8	50
24	H1-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients' Perspective of Effectiveness and Side Effects – A Retrospective Survey Study. PLoS ONE, 2011, 6, e23931.	2.5	47
25	Recognizing mastocytosis in patients with anaphylaxis: Value of KIT D816V mutation analysis of peripheral blood. Journal of Allergy and Clinical Immunology, 2015, 135, 262-264.	2.9	47
26	Development of the Angioedema Control Test—A patientâ€reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1165-1177.	5.7	47
27	An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. Journal of Allergy and Clinical Immunology, 2022, 149, 1683-1690.e7.	2.9	47
28	Antihistamineâ€resistant urticaria factitia successfully treated with antiâ€immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1494-1495.	5.7	46
29	Rupatadine improves quality of life in mastocytosis: a randomized, doubleâ€blind, placeboâ€controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 949-952.	5.7	46
30	Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 869-877.	5.7	45
31	Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021. International Journal of Molecular Sciences, 2021, 22, 2586.	4.1	38
32	Mast Cell-Mediated and Associated Disorders in Pregnancy: A Risky Game with an Uncertain Outcome?. Frontiers in Immunology, 2014, 5, 231.	4.8	37
33	A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs). Journal of Immunological Methods, 2014, 413, 62-68.	1.4	37
34	Anaphylaxis caused by mosquito allergy in systemic mastocytosis. Lancet, The, 2013, 382, 1380.	13.7	35
35	An improved Peltier effectâ€based instrument for critical temperature threshold measurement in cold― and heatâ€induced urticaria. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2043-2045.	2.4	35
36	Clinical Measures of Chronic Urticaria. Immunology and Allergy Clinics of North America, 2017, 37, 35-49.	1.9	34

#	Article	IF	CITATIONS
37	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wiener Klinische Wochenschrift, 2012, 124, 807-814.	1.9	33
38	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3918-3928.	3.8	33
39	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2139-2144.	3.8	31
40	Murine and human mast cell progenitors. European Journal of Pharmacology, 2016, 778, 2-10.	3.5	30
41	Histamine intolerance in patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1774-1777.	2.4	29
42	Mast cells protect from skin tumor development and limit tumor growth during cutaneous <i>de novo</i> carcinogenesis in a <scp>K</scp> itâ€dependent mouse model. Experimental Dermatology, 2014, 23, 159-164.	2.9	27
43	Diagnosis and treatment of chronic inducible urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2550-2553.	5.7	26
44	Selected recent advances in understanding the role of human mast cells in health and disease. Journal of Allergy and Clinical Immunology, 2022, 149, 1833-1844.	2.9	26
45	Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions. Journal of Allergy and Clinical Immunology, 2019, 144, S19-S30.	2.9	24
46	Randomized, doubleâ€blind, placeboâ€controlled study of safety and efficacy of miltefosine in antihistamineâ€resistant chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e363-9.	2.4	23
47	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. Journal of Allergy and Clinical Immunology, 2020, 146, 300-306.	2.9	23
48	Questions and answers in chronic urticaria: where do we stand and where do we go?. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 7-15.	2.4	22
49	In vivo non-invasive staining-free visualization of dermal mast cells in healthy, allergy and mastocytosis humans using two-photon fluorescence lifetime imaging. Scientific Reports, 2020, 10, 14930.	3.3	21
50	The Diagnostic Workup in Chronic Spontaneous Urticaria—What to Test and Why. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2274-2283.	3.8	21
51	Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. British Journal of Dermatology, 2010, 162, 185-190.	1.5	19
52	Development and validation of the mastocytosis activity score. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1489-1496.	5.7	17
53	Chronic urticaria – What does the new guideline tell us?. JDDG - Journal of the German Society of Dermatology, 2018, 16, 584-593.	0.8	17
54	The Henna pigment Lawsone activates the Aryl Hydrocarbon Receptor and impacts skin homeostasis. Scientific Reports, 2019, 9, 10878.	3.3	17

#	Article	IF	CITATIONS
55	The Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers. International Journal of Molecular Sciences, 2022, 23, 2249.	4.1	17
56	Lower IgA Levels in Chronic Spontaneous Urticaria Are Associated With Lower IgE Levels and Autoimmunity. Frontiers in Immunology, 2021, 12, 657211.	4.8	15
57	Detection of KIT D816V mutation in patients with severe anaphylaxis and normal basal tryptase—first data from the Anaphylaxis Registry (NORA). Journal of Allergy and Clinical Immunology, 2019, 144, 1448-1450.e1.	2.9	13
58	ldiopathic mast cell activation syndrome is more often suspected than diagnosed—A prospective realâ€life study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2794-2802.	5.7	12
59	Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2015-2024.	3.8	12
60	Mast Cells Modulate Antigen-Specific CD8+ T Cell Activation During LCMV Infection. Frontiers in Immunology, 2021, 12, 688347.	4.8	11
61	Miltefosine: a novel treatment option for mast cell-mediated diseases. Journal of Dermatological Treatment, 2013, 24, 244-249.	2.2	10
62	Controversies and challenges in the management of chronic urticaria. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 16-24.	2.4	9
63	The male beard hair and facial skin – challenges for shaving. International Journal of Cosmetic Science, 2016, 38, 3-9.	2.6	9
64	Chymase-Cre; Mcl-1fl/fl Mice Exhibit Reduced Numbers of Mucosal Mast Cells. Frontiers in Immunology, 2019, 10, 2399.	4.8	9
65	Severe cold urticaria can point to an underlying clonal mast cell disorder. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2609-2613.	5.7	9
66	A novel approach for studying mast cell–driven disorders: Mast cells derived from induced pluripotent stem cells. Journal of Allergy and Clinical Immunology, 2022, 149, 1060-1068.e4.	2.9	9
67	Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF©. Orphanet Journal of Rare Diseases, 2021, 16, 414.	2.7	8
68	Innovative approaches to avoid electric shavingâ€induced skin irritation. International Journal of Cosmetic Science, 2016, 38, 10-16.	2.6	6
69	Chronische Urtikaria – Was bringt die neue Leitlinie?. JDDG - Journal of the German Society of Dermatology, 2018, 16, 585-595.	0.8	6
70	Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study. Orphanet Journal of Rare Diseases, 2021, 16, 434.	2.7	5
71	Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1171-1172.	0.8	4
72	Generation and Culture of Peripheral CD34+ Stem Cell-Derived Mast Cells (PSCMCs). Methods in Molecular Biology, 2020, 2163, 63-67.	0.9	3

#	Article	IF	CITATIONS
73	Adaptación transcultural del cuestionario Mastocytosis Quality of Life questionnaire (MC-QoL) del alemán al castellano. Actas Dermo-sifiliográficas, 2020, 111, 243-248.	0.4	2
74	Development of tripe palms and soles in a patient with long preâ€existing systemic mastocytosis and newly developed nonâ€small cell lung cancer. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e151-e153.	2.4	0
75	Translation and Cultural Adaptation of the German Mastocytosis Quality of Life Questionnaire (MC-QoL) Into Spanish. Actas Dermo-sifiliográficas, 2020, 111, 243-248.	0.4	0
76	Mastozytose. , 2016, , 1-7.		0
77	Mastozytose. , 2018, , 1979-1985.		0
78	Mastocytoses. , 2020, , 1-8.		0
79	Mast Cell-Mediated Reactions In Vivo. Methods in Molecular Biology, 2020, 2163, 357-365.	0.9	0
80	Mastocytoses. , 2022, , 1965-1972.		0